As oligo manufacturers scale up production from lab-scale to clinical and commercial scales, they may require volumes of hazardous materials that drive additional facility design considerations.
Bill Jarvis
Advertisement
Bill Jarvis is senior fellow, Pharmaceutical Process, at CRB.
Articles by Bill Jarvis
Advertisement
Latest Updated Articles
Oligonucleotide Production FacilitiesPublished: November 15th 2023 | Updated:
Advertisement
Advertisement
Trending on BioPharm International
1
Biologics, Obesity, China Top Financial Trends Reshaping Pharma R&D in J.P. Morgan Report
2
Everything to Know About Cell and Gene Therapy in 2025
3
Overcoming Funding Challenges and Maintaining Optimism in CGTs (Part 1)
4
Why Product-Specific Strategies Matter in Advanced Therapy Manufacturing (Part 3)
5
